- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Ian Manners: Addressing Financial Toxicity for Patients
Vivor has a provider-facing technology platform that empowers providers to address financial toxicity by proactively identifying financial resources for their patients, said Ian Manner, MBA, co-founder, CEO, Vivor.
Vivor has a provider-facing technology platform that empowers providers to address financial toxicity by proactively identifying financial resources for their patients, said Ian Manners, MBA, co-founder, CEO, Vivor.
Transcript (slightly modified)
At Vivor, we make a provider-facing technology platform that really empowers providers to address financial toxicity by proactively identifying financial resources for their patients. So many patients out there, even though they have insurance, end up with a really unaffordable out-of-pocket cost; it could be a deductible, co-insurance, and so on. But, there’s a lot of resources out there that often go underused from pharmaceutical companies and from non-profit foundations. What Vivor’s done is we made it very easy for providers to match patients up with exactly the right set of resources without doing any research or any work. We integrate with their EHR, and so it really gives providers a very effective tool in their tool box to say, “We’re looking for solutions for financial toxicity, and we’re going to get you enrolled in these resources without you even having to think about it.”
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Building Trust, Breaking Barriers: Health Care Leaders Tackle Primary Care Challenges
August 8th 2024On this episode of Managed Care Cast, we're talking with the chief medical officers of CVS Health and Aetna, as well as CVS Health's chief health equity officer, about primary and preventive care engagement, the impact of telehealth, and the role of trust in patient-provider relationships.
Listen
FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML
October 20th 2024The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.
Read More
Frameworks for Advancing Health Equity: LGBTQIA+ Affirming Provider Designation
July 9th 2024Kim Zynn, vice president of UPMC Health Plan's provider network and development relations team, shares how physicians can become LGBTQIA+ affirming providers, which is designated within the health plan.
Listen
